Gendro participated at the World Cancer Congress 2024 as part of a pivotal plenary session organized by The Lancet commission on Women, Power and Cancer.
UICC has closed a successful World Cancer Congress 2024 in Geneva, where more than 2,000 delegates from over 120 countries discussed global strategies and new approaches to addressing essential challenges facing the cancer community.
The World Cancer Congress 2024 in Geneva, Switzerland, took place 17-19 September. Organised by UICC, the event gathered over 2,000 delegates from more than 120 countries, including UICC members, researchers, healthcare professionals, private sector representatives and advocates, to focus on key themes such as cancer prevention, care, and global policy. Read more ….
In the realm of global health policy and research, persistent and historical gender biases continue to permeate a largely patriarchal ecosystem. These biases result in the oversight of crucial gender dimensions and disadvantage women’s health, hindering adequate investment and innovation tailored to address women’s unique and diverse health needs.
Despite growing awareness of these biases and increased efforts by civil society, academia, and the philanthropic sector (such as the White House Initiative on Women’s Health Research, and the Women’s Health Innovation Opportunity Map by NIH and the Bill & Melinda Gates Foundation) to spur gender responsive and inclusive research and innovation to advance women’s health, progress remains slow and fragmented.
In two sessions, we will delve into the landscape of women’s health research and development (R&D), examining the existing barriers and disparities through a gender lens. Our conversation aims to connect the dots between persistent gender biases in research and the transformative potential of a feminist global health policy (FGHP). By shining a spotlight on the barriers and obstacles in advancing women’s health R&D, we seek to explore whether a FGHP holds the potential to accelerate the discovery and enhance the accessibility of new innovations, crucial to interrupting the prevailing health inequities, particularly those that disproportionately affect women.
Part 1 ‘Gender biases in Research & Development’ aims to explore whether a feminist global health policy (FGHP) is the transformative force needed to disrupt and reconstruct a new global health ecosystem to propel gender equality, address health inequities, and accelerate efforts towards social justice.
Our distinguished panel will shed light on lessons learned from the application of feminist foreign policies, exploring promises and pitfalls of these efforts. The discussion will also include valuable recommendations to spur innovation and advance women’s health in all its diversities.
The objectives of this session are to
Examine gender-related barriers and gender disparities in women’s health research and development, identifying challenges hindering innovation.
Explore the potential impact of a Feminist Global Health Policy in accelerating the discovery and accessibility of innovative solutions to address health inequities for women.
Part 2 ‘Drug drought in Women’s Health’ aims to discuss gaps and strengths of the women’s health R&D landscape in the last 20 year. Together with our distinguished panel of diverse stakeholders, we will discuss where the need for innovation is, and how the future of women’s health R&D looks like. In continuation with part 1, the discussion will also include valuable recommendations to spur innovation and advance women’s health in all its diversities.
The objectives of this session :
Examine gender-related barriers and gender disparities in women’s health research and development, identifying challenges hindering innovation.
Explore the potential impact of a Feminist Global Health Policy in accelerating the discovery and accessibility of innovative solutions to address health inequities for women.
Gendro’s Founder and Director joins a fireside chat about gender equity and data with Dr Michelle Kaufman, Director of Gender Equity Unit at the Johns Hopkins Bloomberg School of Public Health.
During the webinar, Shirin Heidari shared the tremendous progress that has been made to recognize the importance of gender and sex in health research and improved awareness of gender gaps and biases.
This special session was organized by the NIH Office of Research on Women’s Health, Sex and Gender in Health and Disease (SGHD) Scientific Interest Group (SIG). The primary focus of the webinar was to delve into the impacts of sex (as a biological variable) and gender (as a social construct) on health and disease throughout the lifespan. The webinar facilitated a conversation to look back at the progress made, and new ongoing efforts and have a forward-looking conversation on how to accelerate progress. following the insightful presentation by Drs. Natasha A. Karp (Biostatistics Director at AstraZeneca) and Barbara Stranger (Professor at the University of Chicago), and Shirin Heidari (President of GENDRO), provided an overview of the development of the SAGER guidelines and its success to date and its potential to driving systemic changes in the research ecosystem.
